Lei et al. detected the mutation of FGFR2 in the mammary gland of a mouse model and found that FGF/FGFR2 drives the development of breast cancer, and inhibiting FGFR2 and blocking immune checkpoints can reduce the number of cancer cells [48]. This evidence concerns the gene FGFR2 and breast carcinoma.